0001567619-20-018006.txt : 20201020
0001567619-20-018006.hdr.sgml : 20201020
20201020165718
ACCESSION NUMBER: 0001567619-20-018006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201020
FILED AS OF DATE: 20201020
DATE AS OF CHANGE: 20201020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Symons Julian A.
CENTRAL INDEX KEY: 0001824727
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 201248783
MAIL ADDRESS:
STREET 1: C/O ALIGOS THERAPEUTICS, INC.
STREET 2: ONE CORPORATE DRIVE, 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2020-10-20
0
0001799448
Aligos Therapeutics, Inc.
ALGS
0001824727
Symons Julian A.
C/O ALIGOS THERAPEUTICS, INC.
1 CORPORATE DRIVE, 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Common Stock
2020-10-20
4
C
0
13671
A
389218
D
Common Stock
2020-10-20
4
C
0
3394
A
392612
D
Common Stock
2020-10-20
4
C
0
1452
A
394064
D
Series A Preferred Stock
2020-10-20
4
C
0
13671
0.00
D
Common Stock
13671
0
D
Series B-1 Preferred Stock
2020-10-20
4
C
0
3394
0.00
D
Common Stock
3394
0
D
Series B-2 Preferred Stock
2020-10-20
4
C
0
1452
0.00
D
Common Stock
1452
0
D
Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
/s/ Lucinda Y. Quan, as attorney-in fact for Julian A. Symons
2020-10-20